Hi there. We are interested in improving the outcomes of Castrate Resistant Prostate Cancer and Metastatic Prostate Cancer. Are there any trials combining anti-PD-1 with CTLA4(-) like that used in Melanoma? Preliminary trials in Prostate Ca show less than 30% response rates with single agents. How do we select the right patients? PD-1 expression? If yes, then what is the cut off? Your thoughts and feedback is appreciated.
Depending on the PD-L1 or PD-1 blocker the level of PD-L1 in the tumour seems to possibly matter to some more than others. In any case the levels in the tumour will have to be stratified vs. response in the analysis.
Various cut offs have been hypothesized to demonstrate significance but data remains premature. ..thanks Jason
CaP cells often down-regulate their B-2 micro floor of the MHC trimer, rendering CTL based therapy ineffective. In addition to PDL-1 expression, look for good MHC markers, and an inflammatory environment can increase PDL-1 through IFN-B. Check TLR 3/7/9 expression on the tumor fibros if you can culture. Good Luck
- Badges
- Science topic